• All
  • Blogs
  • Mentions
  • Press Releases

Pharma Executive, Timothy Wright, Joins Board of Directors

Experienced drug developer and pharma executive, Dr. Timothy Wright, has joined the Abcentra’s Board of Directors.

Abcentra Names Kevin Bacon Chief Executive Officer

Experienced Industry Leader Elevates Research and Development Capabilities, Joins Company At An Important Development Juncture

Treating Arterial Inflammation

Responsible for over 840,400 deaths and nearly 1.8 million cases of heart attack and stroke each year, CVD is the leading cause of death in the U.S.

No More Siloes: Linking Rheumatology and CVD

Although there are evidence-based links between CVD and inflammatory conditions, and associated strong risk factors, they are often ignored when treating patients with either type of condition.

Treating Aortic Valve Disease

Aortic valve stenosis (a severe form of aortic valve disease) is the narrowing of the exit to the left ventricle of the heart. It is the most common form of valve disease, affecting more than one million patients in North America each year.

Abcentra Achieves Manufacturing Milestone

Abcentra completes orticumab clinical batch manufacturing in advance of upcoming psoriasis trial

Finding Treatments for Aortic Valve Stenosis

Aortic valve stenosis is the most common and most serious valve disease problem affecting more than one million patients in North America each year. 

The New Medical Frontier: Understanding the Mechanism of Disease for Better Care

The high cost of health care is not a new discussion. Each day, we are inundated with heartbreaking stories of patients without access to essential therapies due to rising costs or the inability to pay momentous medical bills.

CardioVax Announces Name Change to Abcentra

CardioVax, a privately held, clinical-stage biopharmaceutical company developing novel antibody therapeutics for inflammatory diseases, announced today that it has changed its name to Abcentra.


Glossary of terms used on this website